Research programme: kinase inhibitors - Exelixis

Drug Profile

Research programme: kinase inhibitors - Exelixis

Alternative Names: EXEL 0862; EXEL 2280; EXEL 2819; EXEL 2942; EXEL 6309; EXEL 7647; EXEL-8232; mTORC1/mTORC2 inhibitor (XL388); XL 388

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Aurora kinase A inhibitors; Insulin-like growth factor I inhibitors; Janus kinase-2 inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Phosphoric monoester hydrolase inhibitors; Phosphotransferase inhibitors; Proto oncogene protein c-akt inhibitors; Proto oncogene protein c-kit inhibitors; Raf kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Myeloproliferative disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myeloproliferative disorders in USA (PO)
  • 19 Nov 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top